Remote Tailored Interventions Increased Colonoscopy Screening Despite Cost Barriers
the Cancer Therapy Advisor take:
Remote tailored intervention (TeleCARE) was associated with increased colonoscopy uptake among at-risk relatives of patients with colorectal cancer, according to a study published online in the journal Cancer Epidemiology, Biomarkers & Prevention.
Participants in the study included family members of patients with colorectal cancer who were not up-to-date with colonoscopy screening. The participants were then randomly assigned to one of two groups: TeleCARE (N=232) or an educational brochure (N=249).
Results showed that 42.7% of participants in the TeleCARE intent-to-treat analysis had a medically-verified colonoscopy, compared to 24.1% of participants in the educational brochure group (OR = 2.37; 95% CI: 1.59, 3.52). Cost was identified as a barrier for the majority of both experimental cohorts (TeleCARE=62.5% and educational brochure=57.0%). Individuals in the TeleCARE group not affected by the cost barrier were four times as likely to have a colonoscopy compared to those in the educational brochure group (OR = 3.66; 95% CI: 1.85, 7.24).
Overall, the participants in the TeleCARE group were almost twice as likely to have a colonoscopy compared to their counterparts (OR = 1.99; 95% CI: 1.12, 3.52).
The study suggests that remote interventions could be an effective means of increasing colonoscopy screening regardless of cost barriers.
Remote tailored intervention (TeleCARE) was associated with increased colonoscopy uptake among at-risk relatives for colorectal cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Plastics and Cancer
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC
- Pembrolizumab With Dabrafenib and Trametinib Shows Efficacy, But High TRAEs, in Melanoma
- Assays May Help Researchers Discover Factors Underlying Immunotherapy Response
- Atezolizumab Combo Improved PFS, OS in Stage IV Non-Small Cell Lung Cancer
- Olaparib Maintenance Prolongs PFS Compared With Placebo in Newly Diagnosed Advanced Ovarian Cancer
- Cabozantinib Effective Regardless of PD-L1 Expression in RCC